BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,650,000 | +12.9% | 162,969 | -0.2% | 0.49% | +24.5% |
| Q3 2021 | $2,347,000 | -40.6% | 163,324 | -34.6% | 0.40% | -35.1% |
| Q2 2021 | $3,950,000 | +47.0% | 249,856 | -55.7% | 0.61% | +2.7% |
| Q2 2020 | $2,687,000 | +14.7% | 563,961 | +96.0% | 0.59% | +3.3% |
| Q1 2019 | $2,343,000 | -4.6% | 287,805 | -5.4% | 0.58% | -13.8% |
| Q4 2018 | $2,456,000 | +166.7% | 304,277 | +177.6% | 0.67% | +360.0% |
| Q1 2017 | $921,000 | -9.3% | 109,625 | +23.1% | 0.14% | -9.9% |
| Q3 2015 | $1,015,000 | -41.9% | 89,061 | -23.9% | 0.16% | -21.1% |
| Q2 2015 | $1,746,000 | +108.4% | 116,969 | +36.5% | 0.20% | +20.0% |
| Q3 2014 | $838,000 | -23.3% | 85,721 | 0.0% | 0.17% | -17.9% |
| Q2 2014 | $1,093,000 | -9.8% | 85,721 | -25.2% | 0.21% | -5.0% |
| Q1 2014 | $1,212,000 | +12.4% | 114,548 | -22.6% | 0.22% | +1.4% |
| Q3 2013 | $1,078,000 | – | 148,081 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |